Table 4.
Vβ T cell signatures and Staphylococcus aureus toxin gene profiles of patients with staphylococcal toxic shock syndrome.
| Treatments | Immunological data | Microbiological data | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gender | Antitoxin antibiotic | IVIGa (Dose) | Vβ alterations of CD3+ T cells (%)b | Vβ alterations of CD3+ T cells (%)b | Toxin suspected according to Vβ modification profile | Site of isolation – Infection or carriage strain | Methicillin suscepti-bility | Allele of Agr system | Toxin gene profile | Clonal complexe | |
| Measurement 1 [day post shock onset] | Measurement 2 [day post shock onset] | ||||||||||
| Menstrual staphylococcal toxic shocks | Fc | Yes | Yes (NAd) | Vβ2  (44.4%) [De+4] |
NDf | TSST-1g | Vagina (c)h | MSSAi | 3 | tstj; seak; egcl | CC30 |
| F | Yes | No | Vβ2  (1.1%) [D+1] |
Vβ2 ↔ (10.2%) [D+5] | TSST-1 | Vagina (c) | MSSA | 1 | tst; egc | CC22 | |
| F | Yes | No | Vβ2 (19%) [D+1] |
ND | TSST-1 | Vagina (c) | MSSA | 3 | tst | CC30 | |
| F | Yes | No | Vβ2 (22%) [D+2] |
ND | TSST-1 | Vagina (c) | MSSA | 3 | tst; sea; egc; selum | CC30 | |
| F | Yes | Yes (1g/kg) | Vβ2 (5.7%) [D+1] |
Vβ2 (14.1%) [D+3] |
TSST-1 | Vagina (c) | MSSA | 3 | tst; sea; egc; selu | CC30 | |
| F | Yes | No | Vβ2 (12%) [D+3] |
Vβ2 (27.2%) [D+5] |
TSST-1 | Vagina (c) | MSSA | 3 | tst | CC30 | |
| ccF | Yes | Yes (0.5g/kg) | Vβ2 (29.3%) [D+2] |
ND | TSST-1 | Vagina (c) | MSSA | 3 | tst; sea; egc; selu | CC30 | |
| Non menstrual staphylococcal toxic shocks | Mn | Yes | Yes (2g/kg) | Vβ2 (0.9%) [D+1] |
Vβ2 (52.4%) [D+3] |
TSST-1 | Throat (c) | MSSA | 3 | tst; sea; egc | CC30 |
| M | Yes | Yes (2g/kg) | Vβ2 (27.3%) [D+1] |
ND | TSST-1 | Furuncle (i)o | MSSA | 3 | tst; egc; selu | CC30 | |
| F | Yes | Yes (1g/kg) | Vβ2 (46.5%) [D+4] |
ND | TSST-1 | Blood (i) | MSSA | 3 | tst; sea; egc; selu | CC30 | |
| M | Yes | No | Vβ2 (0.6%) [D+2] |
Vβ2 ↔ (9.9%) [D+4] | TSST-1 | Nose (c) | MSSA | 3 | tst; sea; egc; selu | CC30 | |
| F | Yes | Yes (1g/kg) | Vβ2 (47.6%) [D+4] |
ND | TSST-1 | Superficial wound (i) | MSSA | 3 | tst; sea; egc; selu | CC30 | |
| F | Yes | No | ND | ND | ND | Skin (i) | MRSAp | 2 | tst; secq; sedr; seljs; sellt; egc; selu; seru | CC5 | |
| F | Yes | No | ND | ND | ND | Skin (i) | MSSA | 1 | sec; sell; egc; selu | CC45 | |
| M | No | No | ND | ND | ND | Lung (i) | MSSA | 2 | seb; selpv | ND | |
IVIG, Intravenous immunoglobulins;
Vβ alterations of CD3+ T cells (%), The expression of 24 main Vβ CD3+ T cells was determined by flow cytometry. Since all our staphylococcal toxic shock syndromes were due to toxic shock syndrome toxin-1 (TSST-1), only Vβ2 repertoire was reported according to it's the only Vβ repertoire targeted by TSST-1. Normal adult range for Vβ2 repertoire according to kit manufacturer, 5.84 to 10.76%.
F, female.
NA, not available.
D, day.
ND, not determined.
TSST-1, toxic shock syndrome toxin−1.
(c): carriage strain.
MSSA, Methicillin Susceptible Staphylococcus aureus ;
tst: gene encoding staphylococcal toxic shock toxin 1.
sea, gene encoding staphylococcal enterotoxin A.
egc, enterotoxin gene cluster encoding staphylococcal enterotoxin G, I, M, N, and O.
selu, gene encoding staphylococcal enterotoxin like U.
M, male;
(i): infection strain.
MRSA, Methicillin Resistant Staphylococcus aureus.
sec, gene encoding staphylococcal enterotoxin C.
sed, gene encoding staphylococcal enterotoxin D.
selj, gene encoding staphylococcal enterotoxin like J.
sell, gene encoding staphylococcal enterotoxin like L.
ser, gene encoding staphylococcal enterotoxin R.
selp, gene encoding staphylococcal enterotoxin like P.